Form 4: DEXCOM EVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
DEXCOM's EVP and Chief Legal Officer, Michael Jon Brown, sold 1,700 shares of common stock for $64.85 per share under a pre-arranged 10b5-1 plan.
Summary
- Michael Jon Brown, Executive Vice President and Chief Legal Officer of Dexcom Inc. (DXCM), reported a sale of common stock.
- 1,700 shares of common stock were sold on March 16, 2026, at a price of $64.85 per share.
- The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025.
- Following this sale, Mr. Brown beneficially owns 112,904 shares of common stock.
- This beneficial ownership includes 77,603 unvested restricted stock units (RSUs) with various vesting schedules extending through March 8, 2029.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. It's a routine insider transaction under a 10b5-1 plan, which is a standard practice and does not inherently signal positive or negative company performance.
Future Outlook
The sale was part of a pre-arranged 10b5-1 plan, indicating a planned disposition of shares. The remaining unvested restricted stock units suggest continued long-term incentive alignment with the company's performance.
Industry Context
StockSavvy.ai notes that 10b5-1 plans are common tools for corporate insiders to sell company stock in a pre-scheduled, compliant manner, mitigating concerns about trading on material non-public information. This transaction is a routine disclosure for executive compensation and liquidity management.
Stakeholder Impact
- Minimal direct impact on shareholders as it's a small, pre-planned sale by an executive.
- Provides transparency regarding executive stock ownership changes.
Key Dates
| Date | Description |
|---|---|
| 2024-03-08 | Grant date for 7,237 unvested restricted stock units, vesting through March 8, 2027. |
| 2025-03-08 | Grant date for 19,948 unvested restricted stock units, vesting through March 8, 2028, and 11,399 unvested restricted stock units, vesting through March 8, 2027. |
| 2025-11-26 | Date Mr. Brown adopted the 10b5-1 Plan. |
| 2026-03-08 | Grant date for 39,019 unvested restricted stock units, vesting through March 8, 2029. |
| 2026-03-16 | Transaction date for the sale of 1,700 shares of common stock. |
| 2026-03-18 | Signature date of the filing. |
Recommendation
holdThis Form 4 filing details a routine, pre-planned insider stock sale by an executive under a 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or the executive's confidence, but rather a mechanism for personal financial planning. Therefore, it does not provide sufficient new information to warrant a change from a 'hold' recommendation based solely on this filing.
Keywords
Dexcom, DXCM, Michael Jon Brown, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.